Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK500964PMID: 30000023
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 437608-50-9
Drug Levels and Effects
Summary of Use during Lactation
Lutetium Lu 177 dotatate is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. No information is available on the use of lutetium Lu 177 dotatate during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during lutetium Lu 177 dotatate therapy and for 2.5 months following the last dose, which would usually mean permanently discontinuing breastfeeding of the current infant.
Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at a safe level she may resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[1]
Drug Levels
Lutetium 177 decays to stable hafnium (Hf 177) with a half-life of 6.65 days, by emitting beta radiation with a maximum energy of 0.498 MeV and photonic gamma radiation of 0.208 MeV and 0.113 MeV.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
- Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: Mechanisms, findings, and radiation dosimetry. J Nucl Med. 2000;41:863–73. [PubMed: 10809203]
Substance Identification
Substance Name
Lutetium Lu 177 Dotatate
CAS Registry Number
437608-50-9
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- PubMedLinks to PubMed
- Review Copper Cu 64 Dotatate.[Drugs and Lactation Database (...]Review Copper Cu 64 Dotatate.. Drugs and Lactation Database (LactMed®). 2006
- Review Gallium Ga 68 Dotatate.[Drugs and Lactation Database (...]Review Gallium Ga 68 Dotatate.. Drugs and Lactation Database (LactMed®). 2006
- Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog (177)Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors.[J Nucl Med. 2018]Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog (177)Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors.Zhang J, Wang H, Jacobson O, Cheng Y, Niu G, Li F, Bai C, Zhu Z, Chen X. J Nucl Med. 2018 Nov; 59(11):1699-1705. Epub 2018 Apr 13.
- Dose escalation of an Evans blue-modified radiolabeled somatostatin analog (177)Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors.[Eur J Nucl Med Mol Imaging. 2020]Dose escalation of an Evans blue-modified radiolabeled somatostatin analog (177)Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors.Liu Q, Cheng Y, Zang J, Sui H, Wang H, Jacobson O, Zhu Z, Chen X. Eur J Nucl Med Mol Imaging. 2020 Apr; 47(4):947-957. Epub 2019 Dec 12.
- Safety and efficacy of peptide receptor radionuclide therapy with (177)Lu-DOTA(0)-Tyr(3)-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors.[Ann Nucl Med. 2021]Safety and efficacy of peptide receptor radionuclide therapy with (177)Lu-DOTA(0)-Tyr(3)-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors.Kobayashi N, Takano S, Ito K, Sugiura M, Ogawa M, Takeda Y, Okubo N, Suzuki A, Tokuhisa M, Kaneta T, et al. Ann Nucl Med. 2021 Dec; 35(12):1332-1341. Epub 2021 Sep 17.
- Lutetium Lu 177 Dotatate - Drugs and Lactation Database (LactMed®)Lutetium Lu 177 Dotatate - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...